Linked Life Data

10419856

Source:http://linkedlifedata.com/resource/pubmed/id/10419856

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-9-16
pubmed:abstractText
Preclinical and clinical studies of phosphodiesterase 4 inhibitors have shown that these agents may find utility in a wide range of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and various neurological disorders. The future of this class of drugs will depend upon the ability to demonstrate a reasonable safety margin against emesis and other typical phosphodieserase (PDE4) side effects, as well as in identification of the inflammatory disorder(s) most relevant to PDE4 inhibition.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1367-5931
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
466-73
pubmed:dateRevised
2009-8-25
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
pubmed:affiliation
Institut de Recherche Jouveinal/Parke-Davis, 3-9 Rue de la Loge, BP 100, 94265, FRESNES CEDEX, France. annette.doherty@wl.com
pubmed:publicationType
Journal Article, Review